RT Journal Article SR Electronic T1 Long-term Postoperative Adjuvant Chemotherapy of UFT/LV Improves Survival in a Primary Tumor Resection-Pulmonary Metastasis Model JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2045 OP 2048 VO 28 IS 4B A1 SOTARO SADAHIRO A1 TOSHIYUKI SUZUKI A1 YUJI MAEDA A1 AKIRA TANAKA A1 HIROYASU MAKUUCHI A1 AKEMI KAMIJO A1 CHIEKO MURAYAMA YR 2008 UL http://ar.iiarjournals.org/content/28/4B/2045.abstract AB Background: The optimum regimen and optimum duration of administration of postoperative chemotherapy would vary with the postoperative residual tumor volume. Whether or not prolonged administration of oral uracil/tegafur (UFT) with leucovorin (LV) would prolong the survival period was assessed experimentally. Materials and Methods: Murine models of pulmonary metastasis with different volumes of residual tumor after primary tumor resection were prepared, and the efficacy of 12-week and 4-week oral administration of UFT/LV as postoperative adjuvant chemotherapy was compared. Results: In the model with only a small volume of occult residual tumor after early resection of the primary tumor, the survival period in the 12-week UFT/LV group was significantly increased as compared with that in the untreated group, whereas no significant difference was noted between the 4-week UFT/LV group and the untreated group. Conclusion: Long-term administration of UFT/LV as postoperative adjuvant chemotherapy may be potentially beneficial. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved